Symbols / KALA Stock $2.23 -2.62% KALA BIO, Inc.

Healthcare • Biotechnology • United States • NCM
KALA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Avi Minkowitz
Exch · Country NCM · United States
Market Cap 41.46M
Enterprise Value 32.69M
Income -19.65M
Sales —
FCF (ttm) -19.47M
Book/sh 12.56
Cash/sh 0.47
Employees 6
Insider 10d —
IPO Jul 20, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.33
PEG —
P/S —
P/B 0.18
P/C —
EV/EBITDA -0.98
EV/Sales —
Quick Ratio 5.63
Current Ratio 7.91
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -102.01
EPS next Y -6.67
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-19
Earnings (prior) 2025-11-19
ROA -69.27%
ROE -238.68%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 18.59M
Shs Float 18.59M
Insider Own 1.30%
Instit Own 0.64%
Short Float 0.23%
Short Ratio 0.49
Short Interest 42.59K
52W High 1,030.00
vs 52W High -99.78%
52W Low 2.10
vs 52W Low 6.19%
Beta —
Impl. Vol. —
Rel Volume 0.36
Avg Volume 170.01K
Volume 61.81K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $2.29
Price $2.23
Change -2.62%
About

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data. The company serves biotechnology and pharmaceutical companies. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$2.23
Latest analyst target
3. DCF / Fair value
$-18.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.23
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-29 down HC Wainwright & Co. Buy → Neutral —
2025-09-17 main HC Wainwright & Co. Buy → Buy $35
2025-09-11 main Oppenheimer Outperform → Outperform $33
2025-09-08 init Mizuho — → Outperform $30
2025-05-23 main HC Wainwright & Co. Buy → Buy $12
2025-04-04 reit HC Wainwright & Co. Buy → Buy $15
2025-02-13 reit HC Wainwright & Co. Buy → Buy $15
2024-11-15 reit HC Wainwright & Co. Buy → Buy $15
2024-08-19 reit Oppenheimer Outperform → Outperform $15
2024-05-17 main HC Wainwright & Co. Buy → Buy $18
2024-04-02 main HC Wainwright & Co. Buy → Buy $21
2024-04-01 reit Oppenheimer Outperform → Outperform $15
2023-11-17 main HC Wainwright & Co. Buy → Buy $22
2023-08-11 reit HC Wainwright & Co. Buy → Buy $24
2023-05-10 reit HC Wainwright & Co. — → Buy $24
2023-05-01 reit HC Wainwright & Co. — → Buy $22
2023-04-12 main HC Wainwright & Co. — → Buy $22
2023-03-27 reit HC Wainwright & Co. — → Buy $20
2023-03-06 main HC Wainwright & Co. — → Buy $20
News
RSS: Latest KALA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-23 IWICKI MARK T. Director — 154,894 $0.81 $125,464
2025-10-23 REUMUTH MARY Chief Financial Officer — 33,197 $0.82 $27,544
2025-10-22 BRAZZELL ROMULUS KIM Officer — 46,748 $0.83 $38,801
2025-10-22 BAZEMORE TODD M Director — 47,768 $0.83 $39,647
2025-10-22 KHARABI DARIUS Officer — 20,806 $0.83 $17,269
2025-10-01 BAKER BROS ADVISORS, L.P. Former — 730,408 $1.38 $1,056,722
2025-06-24 IWICKI MARK T. Director — 13,227 $4.01 $53,040
2025-06-24 BAZEMORE TODD M Chief Executive Officer — 4,058 $4.01 $16,273
2025-06-24 REUMUTH MARY Chief Financial Officer — 3,631 $4.01 $14,560
2025-06-24 KHARABI DARIUS Officer — 4,511 $4.01 $18,089
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
3.89
Operating Revenue
0.00
0.00
0.00
-100.00%
3.89
Cost Of Revenue
—
—
0.00
-100.00%
2.56
Reconciled Cost Of Revenue
—
—
0.00
-100.00%
2.56
Gross Profit
—
—
0.00
-100.00%
1.33
Operating Expense
39.03
+14.01%
34.23
-0.27%
34.33
-58.48%
82.69
Research And Development
18.78
-15.00%
22.09
+18.87%
18.59
+5.29%
17.65
Selling General And Administration
23.63
+28.84%
18.34
-10.83%
20.57
-68.38%
65.03
General And Administrative Expense
23.63
+28.84%
18.34
-10.83%
20.57
-68.38%
65.03
Other Gand A
23.63
+28.84%
18.34
-10.83%
20.57
-68.38%
65.03
Other Operating Expenses
-3.38
+45.52%
-6.20
-28.48%
-4.83
—
Total Expenses
39.03
+14.01%
34.23
-0.27%
34.33
-59.73%
85.25
Operating Income
-39.03
-14.01%
-34.23
+0.27%
-34.33
+57.81%
-81.36
Total Operating Income As Reported
-39.16
+4.45%
-40.98
-3.33%
-39.66
+51.46%
-81.71
EBITDA
-23.39
+27.97%
-32.47
+10.01%
-36.08
+2.53%
-37.02
Normalized EBITDA
-32.43
-1.59%
-31.92
+10.27%
-35.57
+56.13%
-81.08
Reconciled Depreciation
0.32
+22.39%
0.26
-14.52%
0.30
-43.58%
0.54
EBIT
-23.70
+27.57%
-32.73
+10.05%
-36.38
+3.12%
-37.56
Total Unusual Items
9.04
+1746.81%
-0.55
-7.65%
-0.51
-101.16%
44.06
Total Unusual Items Excluding Goodwill
9.04
+1746.81%
-0.55
-7.65%
-0.51
-101.16%
44.06
Special Income Charges
9.04
+1746.81%
-0.55
-7.65%
-0.51
-101.16%
44.06
Other Special Charges
-5.79
—
—
2.58
Impairment Of Capital Assets
1.41
0.00
—
—
Restructuring And Mergern Acquisition
-4.66
-948.63%
0.55
+7.65%
0.51
+45.71%
0.35
Net Income
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Pretax Income
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Net Non Operating Interest Income Expense
-2.14
+42.69%
-3.73
-20.11%
-3.10
+53.00%
-6.60
Interest Expense Non Operating
3.28
-43.35%
5.78
-0.53%
5.81
-19.98%
7.27
Net Interest Income
-2.14
+42.69%
-3.73
-20.11%
-3.10
+53.00%
-6.60
Interest Expense
3.28
-43.35%
5.78
-0.53%
5.81
-19.98%
7.27
Interest Income Non Operating
1.14
-44.55%
2.06
-24.16%
2.71
+308.28%
0.66
Interest Income
1.14
-44.55%
2.06
-24.16%
2.71
+308.28%
0.66
Other Income Expense
14.19
+2684.34%
-0.55
+88.49%
-4.77
-111.05%
43.14
Other Non Operating Income Expenses
5.15
—
-4.26
-359.83%
-0.93
Gain On Sale Of Business
—
—
0.00
-100.00%
46.99
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Net Income From Continuing Operation Net Minority Interest
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Net Income From Continuing And Discontinued Operation
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Net Income Continuous Operations
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Normalized Income
-36.02
+5.11%
-37.96
+8.94%
-41.69
+53.10%
-88.88
Net Income Common Stockholders
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Diluted EPS
-165.50
+67.39%
-507.50
+41.50%
-867.50
+41.15%
-1,474.00
Basic EPS
-165.50
+67.39%
-507.50
+41.50%
-867.50
+41.15%
-1,474.00
Basic Average Shares
0.16
+114.65%
0.08
+56.09%
0.05
+59.94%
0.03
Diluted Average Shares
0.16
+114.65%
0.08
+56.09%
0.05
+59.94%
0.03
Diluted NI Availto Com Stockholders
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
9.49
-82.90%
55.48
-0.83%
55.95
-35.56%
86.82
Current Assets
9.49
-82.03%
52.80
-0.14%
52.87
-38.48%
85.94
Cash Cash Equivalents And Short Term Investments
7.56
-85.23%
51.18
+0.56%
50.90
-27.80%
70.50
Cash And Cash Equivalents
7.56
-85.23%
51.18
+0.56%
50.90
-27.80%
70.50
Other Short Term Investments
—
—
—
—
Receivables
—
—
0.24
-96.37%
6.50
Accounts Receivable
—
—
0.12
-40.00%
0.20
Other Receivables
—
—
0.12
-86.89%
0.91
Inventory
—
—
—
0.00
Prepaid Assets
—
—
0.56
-20.49%
0.70
Restricted Cash
—
—
—
0.00
Assets Held For Sale Current
—
—
0.00
-100.00%
7.59
Other Current Assets
1.93
+19.62%
1.62
-18.18%
1.98
+200.61%
0.66
Total Non Current Assets
0.00
-100.00%
2.69
-12.76%
3.08
+250.68%
0.88
Net PPE
0.00
-100.00%
2.44
-12.17%
2.78
+567.79%
0.42
Gross PPE
0.87
-76.85%
3.75
-3.45%
3.89
+137.07%
1.64
Accumulated Depreciation
-0.87
+33.87%
-1.31
-18.38%
-1.11
+9.31%
-1.22
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.00
-100.00%
1.69
-16.49%
2.02
+12556.25%
0.02
Machinery Furniture Equipment
0.87
+0.00%
0.87
+0.00%
0.87
-29.52%
1.23
Construction In Progress
—
0.00
-100.00%
0.10
0.00
Other Properties
—
1.19
+33.56%
0.89
+128.64%
0.39
Leases
—
—
—
—
Other Non Current Assets
—
0.25
-18.27%
0.30
-34.85%
0.46
Total Liabilities Net Minority Interest
2.49
-94.22%
43.15
-10.93%
48.45
-28.60%
67.85
Current Liabilities
2.49
-85.29%
16.96
+103.16%
8.35
-67.51%
25.68
Payables And Accrued Expenses
2.31
-27.98%
3.21
-25.64%
4.32
-48.61%
8.41
Payables
0.99
+57.01%
0.63
-31.66%
0.92
-67.55%
2.83
Accounts Payable
0.99
+57.01%
0.63
-31.66%
0.92
-67.55%
2.83
Current Accrued Expenses
1.33
-48.63%
2.58
-24.02%
3.40
-38.99%
5.58
Pensionand Other Post Retirement Benefit Plans Current
0.18
-92.47%
2.39
-8.64%
2.62
-21.54%
3.33
Current Debt And Capital Lease Obligation
—
10.72
+3108.38%
0.33
-93.34%
5.01
Current Debt
—
10.34
—
5.00
Other Current Borrowings
—
10.34
—
5.00
Current Capital Lease Obligation
0.00
-100.00%
0.38
+13.77%
0.33
+2469.23%
0.01
Current Deferred Liabilities
0.00
-100.00%
0.64
-40.74%
1.07
-77.53%
4.78
Current Deferred Revenue
0.00
-100.00%
0.64
-40.74%
1.07
-74.34%
4.19
Other Current Liabilities
—
—
—
4.15
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
26.20
-34.67%
40.10
-4.89%
42.16
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
21.54
-40.16%
35.99
-5.13%
37.94
Long Term Debt
—
20.10
-41.21%
34.19
-9.88%
37.94
Long Term Capital Lease Obligation
0.00
-100.00%
1.43
-20.29%
1.80
0.00
Non Current Deferred Liabilities
—
—
—
0.00
Other Non Current Liabilities
—
4.66
+13.36%
4.11
-2.70%
4.22
Stockholders Equity
7.00
-43.27%
12.33
+64.34%
7.50
-60.45%
18.97
Common Stock Equity
7.00
-43.28%
12.33
+64.34%
7.50
-60.45%
18.97
Capital Stock
0.03
+383.33%
0.01
+100.00%
0.00
+50.00%
0.00
Common Stock
0.03
+366.67%
0.01
+100.00%
0.00
+50.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
0.56
+357.22%
0.12
+120.75%
0.06
+61.65%
0.03
Ordinary Shares Number
0.56
+357.22%
0.12
+120.75%
0.06
+61.65%
0.03
Additional Paid In Capital
701.87
+3.18%
680.25
+6.80%
636.91
+5.07%
606.18
Retained Earnings
-694.90
-4.04%
-667.92
-6.12%
-629.41
-7.19%
-587.21
Gains Losses Not Affecting Retained Earnings
—
—
0.00
0.00
Total Equity Gross Minority Interest
7.00
-43.27%
12.33
+64.34%
7.50
-60.45%
18.97
Total Capitalization
7.00
-78.43%
32.43
-22.21%
41.69
-26.74%
56.91
Working Capital
7.00
-80.48%
35.84
-19.50%
44.52
-26.11%
60.26
Invested Capital
7.00
-83.65%
42.77
+2.58%
41.69
-32.65%
61.91
Total Debt
0.00
-100.00%
32.25
-11.21%
36.32
-15.43%
42.95
Capital Lease Obligations
0.00
-100.00%
1.81
-14.96%
2.13
+16307.69%
0.01
Net Tangible Assets
7.00
-43.27%
12.33
+64.34%
7.50
-60.45%
18.97
Tangible Book Value
7.00
-43.28%
12.33
+64.34%
7.50
-60.45%
18.97
Current Provisions
—
—
—
0.81
Duefrom Related Parties Current
—
—
0.00
-100.00%
5.39
Preferred Stock Equity
0.00
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-31.99
-8.88%
-29.38
-5.21%
-27.93
+64.61%
-78.91
Cash Flow From Continuing Operating Activities
-31.99
-8.88%
-29.38
-5.21%
-27.93
+64.61%
-78.91
Net Income From Continuing Operations
-26.98
+29.94%
-38.51
+8.74%
-42.20
+5.85%
-44.82
Depreciation Amortization Depletion
0.32
+22.39%
0.26
-14.52%
0.30
-43.58%
0.54
Depreciation And Amortization
0.32
+22.39%
0.26
-14.52%
0.30
-43.58%
0.54
Other Non Cash Items
-2.97
-231.37%
2.26
+194.60%
-2.39
-204.32%
2.29
Stock Based Compensation
7.00
-16.62%
8.39
+12.41%
7.46
+6.49%
7.01
Asset Impairment Charge
1.41
0.00
—
—
Operating Gains Losses
-5.24
—
—
-44.41
Gain Loss On Sale Of PPE
0.55
0.00
—
—
Change In Working Capital
-5.52
-210.34%
-1.78
-120.00%
8.89
+1711.61%
0.49
Change In Receivables
—
—
0.08
-99.48%
15.14
Changes In Account Receivables
—
—
0.08
-99.48%
15.14
Change In Inventory
—
0.00
-100.00%
7.54
+341.69%
1.71
Change In Prepaid Assets
-0.32
-188.30%
0.36
-93.85%
5.83
+390.39%
-2.01
Change In Payables And Accrued Expense
-3.54
-94.34%
-1.82
+57.95%
-4.33
+69.10%
-14.00
Change In Accrued Expense
-3.89
-154.78%
-1.53
+36.91%
-2.42
+79.69%
-11.93
Change In Payable
0.36
+223.02%
-0.29
+84.72%
-1.90
+8.29%
-2.08
Change In Account Payable
0.36
+223.02%
-0.29
+84.72%
-1.90
+8.29%
-2.08
Change In Other Current Assets
0.14
0.00
+100.00%
-0.14
0.00
Change In Other Current Liabilities
-1.81
-468.34%
-0.32
-2353.85%
-0.01
+96.22%
-0.34
Investing Cash Flow
-0.01
+92.79%
-0.21
+51.52%
-0.43
-100.68%
62.72
Cash Flow From Continuing Investing Activities
-0.01
+92.79%
-0.21
+51.52%
-0.43
-100.68%
62.72
Net PPE Purchase And Sale
-0.01
+92.79%
-0.21
+63.06%
-0.56
-182.91%
-0.20
Purchase Of PPE
-0.01
+92.79%
-0.21
+65.90%
-0.61
-94.89%
-0.31
Sale Of PPE
—
0.00
-100.00%
0.05
-58.77%
0.11
Capital Expenditure
-0.01
+92.79%
-0.21
+65.90%
-0.61
-94.89%
-0.31
Net Investment Purchase And Sale
—
0.00
-100.00%
0.13
+1575.00%
0.01
Purchase Of Investment
—
0.00
+100.00%
-9.87
-97.64%
-4.99
Sale Of Investment
—
0.00
-100.00%
10.00
+100.00%
5.00
Net Business Purchase And Sale
—
—
0.00
-100.00%
62.91
Purchase Of Business
—
—
—
—
Gain Loss On Sale Of Business
—
—
0.00
+100.00%
-46.99
Net Intangibles Purchase And Sale
—
—
—
0.00
Purchase Of Intangibles
—
—
—
0.00
Financing Cash Flow
-11.62
-138.89%
29.88
+251.23%
8.51
+207.10%
-7.94
Cash Flow From Continuing Financing Activities
-11.62
-138.89%
29.88
+251.23%
8.51
+207.10%
-7.94
Net Issuance Payments Of Debt
-22.50
-346.09%
-5.04
+49.55%
-10.00
+75.02%
-40.04
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-22.50
-346.09%
-5.04
+49.55%
-10.00
+75.02%
-40.04
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-22.50
-346.09%
-5.04
+49.55%
-10.00
+75.02%
-40.04
Net Long Term Debt Issuance
-22.50
-346.09%
-5.04
+49.55%
-10.00
+75.02%
-40.04
Net Common Stock Issuance
9.13
-65.43%
26.43
+42.56%
18.54
-41.70%
31.80
Proceeds From Stock Option Exercised
0.07
-5.19%
0.08
+67.39%
0.05
-84.72%
0.30
Net Other Financing Charges
-0.12
-0.84%
-0.12
+94.17%
-2.04
—
Changes In Cash
-43.62
-15353.15%
0.29
+101.44%
-19.85
+17.75%
-24.13
Beginning Cash Position
51.18
+0.56%
50.90
-28.06%
70.75
-25.44%
94.88
End Cash Position
7.56
-85.23%
51.18
+0.56%
50.90
-28.06%
70.75
Free Cash Flow
-32.01
-8.16%
-29.59
-3.69%
-28.54
+63.98%
-79.22
Interest Paid Supplemental Data
2.70
-41.41%
4.61
-0.22%
4.62
-22.46%
5.96
Amortization Of Securities
—
—
—
—
Common Stock Issuance
9.13
-65.43%
26.43
+42.56%
18.54
-41.70%
31.80
Issuance Of Capital Stock
10.93
-68.73%
34.96
+70.54%
20.50
-35.52%
31.80
Net Preferred Stock Issuance
1.80
-78.92%
8.54
+334.50%
1.97
0.00
Preferred Stock Issuance
1.80
-78.92%
8.54
+334.50%
1.97
0.00
Sale Of Business
—
—
0.00
-100.00%
62.91
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category